title stringlengths 1 1.19k | keywords stringlengths 0 668 | concept stringlengths 0 909 | paragraph stringlengths 0 61.8k | PMID stringlengths 10 11 |
|---|---|---|---|---|
Declarations | PMC10303338 | |||
Ethics approval and consent to participate | Ethics approval for this study was provided by the St. Michael’s Hospital Research Ethics Board (Toronto, ON) and all participants provided informed consent. | PMC10303338 | ||
Consent for publication | Not applicable. | PMC10303338 | ||
Competing interests | HT | CDM has received advisory board honoraria/consulting fees from Amgen, AstraZeneca, BioAge, Boehringer Ingelheim, and PhaseBio, and honoraria for DSMB membership from Beth Israel Deaconess Medical Center, Cerus and Takeda. HT reports personal fees from the Canadian Medical and Surgical Knowledge Translation Research Gro... | PMC10303338 | |
References | PMC10303338 | |||
Background | HDN | The mosquito landing rate measured by human landing catches (HLC) is the conventional endpoint used to evaluate the impact of vector control interventions on human-vector exposure. Non-exposure based alternatives to the HLC are desirable to minimize the risk of accidental mosquito bites. One such alternative is the hum... | PMC10318828 | |
Methods | HDN | Two experiments to evaluate the protective efficacy of (1) a VPSR and (2) ITC, were performed. A block randomized cross-over design over 32 nights was carried out with both the HLC or HDN. Eight replicates per combination of collection method and intervention or control arm were conducted. For each replicate, 100 | PMC10318828 | |
Results | HDN | For the VPSR, the protective efficacy was similar for the two methods: 99.3%, 95% CI (99.5–99.0) when measured by HLC, and 100% (100, Inf) when measured by HDN where no mosquitoes were caught (interaction test p = 0.99). For the ITC, the protective efficacy was 70% (60–77%) measured by HLC but there was no evidence of ... | PMC10318828 | |
Conclusions | bite, HDN | INTERACTIONS | Interactions between mosquitoes, bite prevention tools and the sampling method may impact the estimated intervention protective efficacy. Consequently, the sampling method must be considered when evaluating these interventions. The HDN is a valid alternative trapping method (relative to the HLC) for evaluating the impa... | PMC10318828 |
Keywords | PMC10318828 | |||
Background | malaria, HLCs, HDN | MALARIA, DISEASE, DISEASES | The human-mosquito contact rate is an essential parameter for determining disease risk in a given area and reducing human-mosquito exposure is essential for reducing the risk of diseases such as malaria [Human landing catch set-up in the temporary structureIn response to these challenges, a variety of possible alternat... | PMC10318828 |
Methods | PMC10318828 | |||
Study site | This evaluation was conducted in Kasetsart University’s SFS in Pu Teuy Village, Sai Yok District, Kanchanaburi Province, Thailand. Experimental chambers (9 × 4 × 3 m) of the SFS structure were positioned at least 20 m apart to minimize any spillover effect where the chamber containing the intervention impacts the behav... | PMC10318828 | ||
Mosquito bite prevention interventions | HDN | Two interventions were included in this evaluation. The first is a transfluthrin-based VPSR that was hung from the open structure’s eaves. For this evaluation, two units of this product were hung from two opposite sides of the open structure, per manufacturer’s instructions. Note, due to limited space in the chambers, ... | PMC10318828 | |
Experimental design | The evaluation was conducted over 32 nights using a block randomized cross-over design with 16 nights of collection for each of the two interventions (Fig. Experimental design of the trap evaluation. | PMC10318828 | ||
Mosquitoes and mosquito collection | HDN, a mouth | KU’s HLCs were conducted for 45 min during each hour of the six-hour replicate, allowing for a 15-min break per collection hour. To conduct the HLCs, a collector sat on a chair in the centre of the temporary structure and collected mosquitoes with a mouth aspirator as mosquitoes landed on the lower leg between the knee... | PMC10318828 | |
Data analysis | The OR of the released | PMC10318828 | ||
Discussion | HDN, bite | This study evaluated the performance of two different mosquito trapping methods, the HLC and the HDN, for estimating the effect on mosquito landing rates of two intervention types characterized by contrasting modes of action. The study results indicated that the primary mode of action of each intervention had a substan... | PMC10318828 | |
Conclusion | bite, irritancy | This study indicates that HDNs may be a suitable replacement for HLC for evaluating VPSRs in the field. However, for evaluating ITCs and other similarly acting interventions that function through short range modes of action and tarsal contact (such as, topical repellents), there are no known, validated alternative trap... | PMC10318828 | |
Acknowledgements | The authors thank the data collectors for their diligent work collecting mosquitoes throughout the study. | PMC10318828 | ||
Author contributions | Project conceptualization: SJM, NFL, TC; Project design: SJM, NFL, EV, AR, TC, DM; Project implementation and data collection: TC, MS; Data entry: MS; Data analysis: EV, AR, SJM; Drafting manuscript: EV; Revising and substantially contributing to manuscript: EV, AR, SJM, MS, TC, NFL, DM, AT. | PMC10318828 | ||
Funding | This study was funded by the Australia Department of Foreign Affairs and Trade (DFAT) through the Innovative Vector Control Consortium (IVCC), Liverpool, United Kingdom (Grant number A134328). The funding body had no role in the study design, collection, data analysis, data interpretation, or drafting of manuscript. | PMC10318828 | ||
Availability of data and materials | Data supporting the analysis, outcomes, and conclusions of this article are available upon request to the corresponding author. | PMC10318828 | ||
Declarations | PMC10318828 | |||
Ethics approval and consent to participate | Ethics approval for the study was approved by the Research Ethics Review Committee for Research Involving Human Research Participants, Kasetsart University (No. CAO63/035) and field research station was provided by the Royal Thai Armed Forces Development Command, Ministry of Defense and the Kasetsart University Researc... | PMC10318828 | ||
Consent for publication | Not applicable. | PMC10318828 | ||
Competing interests | The authors declare they have no competing interests. | PMC10318828 | ||
References | PMC10318828 | |||
2. Materials and Methods | PMC10255291 | |||
2.1. Participants | stroke, mental disorder, cardiac disease, diabetes | CHRONIC RENAL FAILURE, JOINT DISORDER, HYPERLIPIDEMIA, GYNECOLOGICAL DISEASE, STROKE, CARDIAC DISEASE, HYPERTENSION, DIABETES | We recruited middle-aged and elderly community-dwelling adults from Japan. Ninety-eight participants were recruited through advertisements published in the local press and posters at community health and recreation centers. Thirty-two individuals who were performing habitual exercise; were taking anti-hyperlipidemic, a... | PMC10255291 |
2.2. Study Design | After informed consent for participation in the study was obtained, allocation was performed using computer-generated random numbers for each sex. In this study, using a randomized controlled intervention trial with a double-blind study design, participants were randomly divided into four groups: the sedentary-control ... | PMC10255291 | ||
2.3. Resistance Training Intervention | Participants performed resistance training sessions using elastic bands (THERABAND, The Hygenic Corporation, Akron, OH, USA) in each participant’s home in the evening (7:00–8:00 p.m.); sessions took place 3 days per week on non-consecutive days for 12 weeks. Participants were supervised by experienced trainers in all t... | PMC10255291 | ||
2.5. Outcome Measures | PMC10255291 | |||
2.5.1. Body Composition | Body weight and height were measured to the nearest 0.1 cm and 0.1 kg, respectively. Body mass index (BMI; kg/m | PMC10255291 | ||
2.5.2. Physical Activity, Energy Intake, and Nutritional Status | The physical activity levels were assessed using the short form of the International Physical Activity Questionnaire (IPAQ-SF), as previously described [ | PMC10255291 | ||
2.5.3. Muscle Quantity and Quality Indexes | To assess the muscle thicknesses of the anterior and posterior femoris muscles and the echo intensity of the rectus femoris muscle, we used a B-mode ultrasound device with 3.4–8.0 MHz linear-array probe (Vscan dual probe, GE Healthcare, Chicago, IL, USA). Ultrasound images consistently set the following parameters: fre... | PMC10255291 | ||
2.5.4. Cardiometabolic Parameters | DBP) blood pressures | All participants sat quietly for 30 min, and brachial systolic (SBP) and diastolic (DBP) blood pressures and heart rate (HR) were measured in duplicate in the sitting position at rest (HEM-7120, OMRON Healthcare, Kyoto, Japan).The sample in serum was immediately collected via centrifuge (1500× | PMC10255291 | |
2.6. Statistical Analysis | All values were expressed as mean ± standard deviation (SD). Statistical analysis of each parameter was carried out using two-way analysis of variance (ANOVA) for repeated measures (time × group). One-way ANOVA was used to compare the differences in changes from baseline to 12 weeks among the four groups. A post hoc co... | PMC10255291 | ||
3. Results | PMC10255291 | |||
3.1. Participant Characteristics and Nutritional Status | The participant flowchart for this study is shown in No significant differences in age, height, body weight, BMI, percent body fat, daily physical activity, or daily total energy intake were observed among the four groups before and after the intervention (Additionally, no significant differences in the main nutritiona... | PMC10255291 | ||
3.2. Muscle Quantity and Quality Indices | No significant differences were observed in anterior and posterior femoris muscle thickness, echo intensity for the rectus femoris, normal walking speed, single-leg stance test, five times sit-to-stand test, and grip strength before and after the interventions among the four groups (Furthermore, changes in the posterio... | PMC10255291 | ||
3.3. Cardiometabolic Parameters | TG | No significant differences in SBP, DBP, HR, Total-Cho, HDL, TG, or HbA1c before and after the interventions were observed among the four groups ( | PMC10255291 | |
4. Discussion | fibrosis | FIBROSIS | Our main findings demonstrated that in healthy middle-aged and older adults, 12-week In the present study, 12-week Aging accelerates muscle fibrosis, which results in decreased muscle quality [This study revealed that, among the cardiometabolic risk factors, HbA1c decreased in the sedentary and low-intensity resistance... | PMC10255291 |
5. Conclusions | In this study, we revealed that 12-week | PMC10255291 | ||
Author Contributions | Conceptualization, M.I.; Data curation, K.I. (Keiko Iemitsu), S.F., M.U., K.I. (Kenichiro Inoue) and M.I.; Formal analysis, K.I. (Keiko Iemitsu), Y.S. and M.I.; Funding acquisition, M.I.; Investigation, K.I. (Keiko Iemitsu), S.F., M.U., K.I. (Kenichiro Inoue) and M.I.; Methodology, Y.S. and M.I.; Project administration... | PMC10255291 | ||
Institutional Review Board Statement | The present study was performed in accordance with the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of Ritsumeikan University (approval number: BKC-2021-006; approval date: 30 June 2021). | PMC10255291 | ||
Informed Consent Statement | Informed consent was obtained from all the subjects involved in the study. | PMC10255291 | ||
Data Availability Statement | The data presented in this study are available upon request from the corresponding author. | PMC10255291 | ||
Conflicts of Interest | The authors declare no conflict of interest. | PMC10255291 | ||
References | anterior femoris muscle thickness | Participant flow chart.Change in anterior femoris muscle thickness ((Comparison of subject characteristics before and after interventions.Data are means and SD. Sed+PL: sedentary-control and placebo intake group, Sed+Dio: sedentary-control and Nutritional status before and after interventions.Data are means and SD. Sed... | PMC10255291 | |
Objective | EPITHELIAL OVARIAN CANCER | Academic Editor: Dawei Cui The aim of this study was to explore prognostic factors, develop and internally validate a prognostic nomogram model, and predict the cancer-specific survival (CCS) of epithelial ovarian cancer (EOC) patients with pelvic exenteration (PE) treatment. | PMC10449593 | |
Methods | A total of 454 EOC patients from the Surveillance, Epidemiology, and End Results (SEER) database were collected according to the inclusion criteria and randomly divided into the training ( | PMC10449593 | ||
Results | In the training cohort, age, histological type, Federation of Gynecology and Obstetrics (FIGO) stage, number of examined lymph nodes, and number of positive lymph nodes were found to be independent prognostic factors of postoperative CSS. A practical nomogram model of EOC patients with PE treatment was constructed bas... | PMC10449593 | ||
Conclusion | Our nomogram exhibited satisfactory survival prediction and prognostic discrimination. It is a user-friendly tool with high clinical pragmatism for estimating prognosis and guiding the long-term management of EOC patients with PE treatment. | PMC10449593 | ||
1. Introduction | Ovarian cancer, aggressive disease | OVARIAN CANCER, RECURRENCE, EPITHELIAL OVARIAN CANCER, METASTASES | Ovarian cancer (OC) is an aggressive disease characterized by its occult property and high rate of recurrence, making iterative cytoreduction a potentially beneficial approach. Among OC cases, epithelial ovarian cancer (EOC) accounts for approximately 90% of cases and represents the most prevalent histological type [Wh... | PMC10449593 |
2. Patients and Method | PMC10449593 | |||
2.1. Study Cohort Selection | Patient information was obtained using SEER | PMC10449593 | ||
2.2. Variable Collection and Reclassification | tumor | TUMOR | The diagnosis and treatment process of EOC patients in the SEER database in the past period were reviewed to identify prognostic factors for CSS. We obtained the following variables of selected patients from the SEER database directly: age at diagnosis, race, year of diagnosis, marital status, histological type, tumor ... | PMC10449593 |
2.3. Statistical Analysis | All statistical analysis was performed using | PMC10449593 | ||
3. Results | PMC10449593 | |||
3.1. Demographic and Clinical Characteristics | The detailed process of patient selection is shown in | PMC10449593 | ||
3.2. Optimal Cutoff of Age, Lymph Nodes, and Tumor Size | Multicollinearity bias between the number of positive lymph nodes and lymph nodes examined was first evaluated by calculating the variance inflation factor (VIF). As is shown in Supplementary | PMC10449593 | ||
3.3. Independent Predictors Analysis for CSS of EOC Patients with PE Treatment | REGRESSION | The univariate and multivariate stepwise Cox regression models were performed in the training cohort ( | PMC10449593 | |
3.4. Development of a Nomogram of CSS in Training Cohort | The nomogram was constructed by incorporating the above-identified independent prognostic variables to predict the 3-, and 5-year CSS in EOC patients with PE treatment ( | PMC10449593 | ||
3.5. Validation of Nomogram in Training Cohort and Validation Cohort | The discrimination of the nomogram was assessed by time-dependent ROC analysis in both the training cohort and validation cohort (Figures The discrimination of this nomogram was further assessed by the bootstrap validation with 1000 resamplings. The bootstrap-corrected Cindex of the nomogram was 0.72 (95% CI: (0.66, 0.... | PMC10449593 | ||
4. Discussion | ovarian cancer, gynecologic malignancies, gynecological recurrent cancer | OVARIAN CANCER, ADVANCED CANCER | Clinical treatment of gynecological recurrent cancer and advanced cancer is very limited. Recently, with the deepening of collaboration of multidisciplinary technology, PE combined with organ function reconstruction has been gradually applied clinically by some doctors in gynecologic malignancies [It could be summarize... | PMC10449593 |
4.1. Limitations | tumor | TUMOR, COMPLICATIONS | First, the SEER database only provides a collection of patients in the United States, and the nomogram constructed in this study has not been demonstrated to be applicable to other regions. Meanwhile, this nomogram was only validated by dividing the total cases into training group and validation group. Therefore, furth... | PMC10449593 |
5. Conclusion | In summary, we found that age, histological type, FIGO stage, number of examined lymph nodes, and number of positive lymph nodes were independent prognostic factors of CSS in EOC patients with PE treatment. We successfully developed a predictive nomogram of 3-year and 5-year CSS which has been demonstrated to present l... | PMC10449593 | ||
Acknowledgments | This study was supported by grants from Young Scholars Fostering Fund of the First Affiliated Hospital of Nanjing Medical University (PY2022032), Special Fund project of Laboratory Medicine Research of Jiangsu Medical Association (SYH-3201160-0056), the National Natural Science Foundation of China (No. 82273199), Natur... | PMC10449593 | ||
Data Availability | The data supporting the findings of this study are available upon request from the corresponding author. | PMC10449593 | ||
Ethical Approval | This study was exempted by the Institutional Ethics Committee of the First Affiliated Hospital of Nanjing Medical University since data in the SEER database are anonymous and open access to the public. | PMC10449593 | ||
Consent | Written informed patient consent for participation was not needed for SEER database data in accordance with the national legislation and the institutional requirements. | PMC10449593 | ||
Disclosure | Xin Fu and Lei Zhang are co-first authors. | PMC10449593 | ||
Conflicts of Interest | The authors declare that there are no conflicts of interest. | PMC10449593 | ||
Authors' Contributions | Shuna | Ting Wang conceptualized and designed the research, analyzed data, and wrote the manuscript. Xin Fu and Lei Zhang curated data, investigated the study, and developed methodology. Shuna Liu and Ziqi Tao curated data and investigated the study. Fang Wang conceptualized and designed the research, supervised the study, and... | PMC10449593 | |
Supplementary Materials | tumor | REGRESSION, TUMOR | Supplementary Table 1: Univariate and multivariable Cox regression analyses of CSS (Click here for additional data file.Patient selection flowchart.Optimal cutoff values determination of continuous variables and Kaplan–Meier curves stratified by the values using x-tile software. (a) Ages were split into two groups: ≤70... | PMC10449593 |
Abstract | ALS | Co‐first authors.Organizations within the Pooled Resource Open‐Access ALS Clinical Trials Consortium are listed in the Acknowledgments. | PMC10723227 | |
Objective | death, ALS | AMYOTROPHIC LATERAL SCLEROSIS | Sodium phenylbutyrate and taurursodiol (PB and TURSO) was evaluated in amyotrophic lateral sclerosis (ALS) in the CENTAUR trial encompassing randomized placebo‐controlled and open‐label extension phases. On intent‐to‐treat (ITT) survival analysis, median overall survival (OS) was 4.8 months longer and risk of death 36%... | PMC10723227 |
Methods | ALS | Clinical trial control participants from the PRO‐ACT database who met prespecified eligibility criteria were propensity score matched 1:1 with PB and TURSO‐randomized CENTAUR participants using prognostically significant covariates in ALS. | PMC10723227 | |
Results | Baseline characteristics including propensity score–matched covariates were generally well balanced between CENTAUR PB and TURSO ( | PMC10723227 | ||
Interpretation | ALS | This analysis suggests potentially greater survival benefit with PB and TURSO in ALS without placebo‐to‐active crossover than seen on ITT analysis in CENTAUR. Analyses using well‐matched external controls may provide additional context for evaluating survival effects in future ALS trials. | PMC10723227 | |
Introduction | ALS | The efficacy and safety of an oral, fixed‐dose combination of sodium phenylbutyrate and taurursodiol (PB and TURSO [RELYVRIOOLE phases provide an opportunity for longer‐term assessment of survival outcomes in trials with randomized placebo‐controlled phases of short duration in addition to increasing access to investig... | PMC10723227 | |
Methods | PMC10723227 | |||
Analysis cohorts | ALS | AMYOTROPHIC LATERAL SCLEROSIS | During the conduct of the CENTAUR trial, eligible participants were in the randomized phase from June 2017 to September 2019 and in the OLE phase from March 2018 to March 2021. CENTAUR trial eligibility criteria allowed for the stable use of riluzole and edaravone before and during the trial. Survival results for the C... | PMC10723227 |
Standard protocol approvals, registrations, and participant consents | The clinical study protocol for CENTAUR was approved by a central institutional review board (the Partners Human Research Committee) for all trial sites, and participants provided written informed consent before entering each trial phase. | PMC10723227 | ||
Statistical analysis methods | death | SENSITIVITY | Overall survival analysis was conducted for 1:1 propensity score–matched individuals from the PRO‐ACT external control group and the CENTAUR PB and TURSO group. Overall survival (time to death) was defined as the time from date of randomization to date of death due to any cause. Median overall survival and IQRs were es... | PMC10723227 |
Results | SE, ALS | AMYOTROPHIC LATERAL SCLEROSIS, AMYOTROPHIC LATERAL SCLEROSIS | A total of 134 individuals in PRO‐ACT met inclusion criteria for this analysis and had known mortality information (full analysis set; Fig. Baseline characteristics.Data are presented as mean (SD), range unless otherwise noted.ALS, amyotrophic lateral sclerosis; ALSFRS‐R, Amyotrophic Lateral Sclerosis Functional Rating... | PMC10723227 |
Discussion | ALS | To estimate the treatment effect of PB and TURSO on survival in ALS in the absence of the placebo‐to‐active crossover that occurred in the OLE phase of the CENTAUR trial, we compared overall survival in those randomized to PB and TURSO with an external, PB and TURSO‐naïve control group from PRO‐ACT, the largest ALS cli... | PMC10723227 | |
Funding information | ALS | Funding for the CENTAUR trial was provided by Amylyx Pharmaceuticals, Inc., ALS Finding a Cure | PMC10723227 | |
Author Contributions | SP, MQ, AVS, MV, YW, JT, and MC contributed to the drafting and revision of the manuscript for content. All authors provided final approval of the manuscript for submission. SP, AVS, MC, and the PRO‐ACT Consortium played major roles in the acquisition of data. SP, MQ, AVS, MV, YW, JT, and MC analyzed and/or interpreted... | PMC10723227 | ||
Conflict of Interest | ALS | S. Paganoni reports research grants from the National Institutes of Health, Alector Therapeutics, Biohaven, Cytokinetics, Anelixis Pharmaceuticals, Revalesio Corporation, UCB, Clene, Prilenia, Seelos Therapeutics, Calico, and Denali Therapeutics unrelated to this manuscript; consulting fees from Amylyx Pharmaceuticals,... | PMC10723227 | |
Supporting information |
Table S1
Click here for additional data file. | PMC10723227 | ||
Acknowledgments | ALS | AMYOTROPHIC LATERAL SCLEROSIS 1 | The authors wish to thank the individuals who participated in the CENTAUR trial, as well as their caregivers and families; the NEALS site staff and the staff at the Coordination Center at the NCRI, Healey & AMG Center for ALS, Massachusetts General Hospital, and Barrow Neurological Institute; and The ALS Association fo... | PMC10723227 |
References | PMC10723227 | |||
Subject terms | Cognitive Impairment, HAMD, Anxiety, anxiety, cognitive impairment, somatic pain, pain, depressive disorder, MDD, depression, Depression, NRS | CORTEX | This study aims to explore changes in depression and pain for major depressive disorder (MDD) patients with somatic pain after repetitive transcranial magnetic stimulation (rTMS) using the event-related potentials (ERPs) technique. Eighty MDD patients with somatic pain were randomly assigned to drug therapy (DT) and co... | PMC10589316 |
Introduction | cognitive impairment, Pain, pain, depressive disorder, cognitive dysfunction, depressive, MDD, depression | CORTEX | Pain is one of the most common symptoms in patients with major depressive disorder (MDD), being present in 65% of casesCognitive impairment is another common and often persistent symptom of MDD. Patients with pain and cognitive impairment are more challenging to treat and have longer treatment durations. Furthermore, c... | PMC10589316 |
Results | PMC10589316 | |||
Characteristics of participants | HAMD, Anxiety, pain, Depression, NRS | DISEASE | In total, 37 patients in the DT group and 38 in the CT group completed the study with a 92.5% and 95.0% completion rate, respectively. Three cases in the DT group were dropped after 3 weeks for taking other drugs. In the CT group, two cases were lost during the follow-up––one due to work and another who believed that t... | PMC10589316 |
Discussion | cognitive impairment, anxiety, somatic pain, pain, MDD, depression | REMISSION | To our knowledge, this was the first study examining the primary changes in ERPs, improvements and effects of a combination treatment with rTMS and antidepressants on depression, pain and cognitive function in untreated MDD patients with somatic pain. Our findings highlighted that rTMS combined with antidepressants led... | PMC10589316 |
Conclusion | MDD, somatic pain, cognitive impairment, anxiety | SECONDARY | Our results highlight that therapy involving rTMS in combination with antidepressants is an effective method for rapid symptom improvement in MDD patients with somatic pain. The combination therapy was helpful for many secondary symptoms such as cognitive impairment, and anxiety. | PMC10589316 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.